Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Idarubicin + Daunorubicin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Idarubicin + daunorubicin is a combination of two anthracycline antineoplastic agents primarily used in the treatment of acute leukemias, especially acute myeloid leukemia (AML). Both drugs act as DNA intercalators and inhibitors of topoisomerase II, leading to DNA strand breaks and inhibition of DNA replication and transcription. Idarubicin is a derivative of daunorubicin with greater potency and improved intracellular accumulation, resulting in stronger antileukemic effects. These agents are cell cycle-nonspecific cytotoxics that induce apoptosis through multiple mechanisms including free radical generation and interference with gene expression. The combination may be used in specific chemotherapy regimens for refractory or relapsed AML or ALL[1][5][6][8].
- Brand names
- CerubidineIdamycin
- Other names
- daunomycin4-demethoxydaunorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNATOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on Idarubicin + Daunorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Idarubicin + Daunorubicin.